Search Within

Genitourinary Oncology Service

Formats
  1. Journal Article (2795)
  2. Meeting Abstract (2526)
  3. Review (121)
  4. Book Section (83)
  5. Editorial (57)
  6. Correspondence (34)
  7. Conference Paper (29)
  8. Guidelines (25)
  9. Research Letter (18)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Solid Tumor Oncology Division (5696)
  2. Department of Medicine (5686)
  3. GSK Faculty (1659)
  4. Human Oncology and Pathogenesis Program (1158)
  5. Department of Pathology and Laboratory Medicine (1130)
  6. Surgery (1021)

More Groups

People
  1. Robert Motzer (1252)
  2. Howard Scher (1133)
  3. David Solit (786)
  4. Dean Bajorin (664)
  5. Michael Morris (588)
  6. Jonathan Rosenberg (525)

More People

Years
  1. 2025 (204)
  2. 2024 (294)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1713)
  2. Annals of Oncology (304)
  3. Clinical Cancer Research (283)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (123)

More Publications

Publishers
  1. American Society of Clinical Oncology (1780)
  2. American Association for Cancer Research (690)
  3. Oxford University Press (414)
  4. Elsevier Science, Inc. (396)
  5. Elsevier Inc. (380)
  6. Nature Publishing Group (304)

More Publishers

Results (5696)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Diagnostic performance of (18)F-DCFPyL in the OSPREY Trial: A prospective phase 2/3 multicenter study of (18)F-DCFPyL PET/CT imaging in patients (Pts) with known or suspected metastatic prostate cancer (mPC)
    Meeting Abstract

    Morris, M. J.; Durack, J. C.; Alva, A. S.; Vargas, H. A.; Piert, M.; Pachynski, R. K.; Pouliot, F.; Beauregard, J. M.; Preston, M. A.; Choudhury, A. D.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Platinum-based chemotherapy in metastatic prostate cancer with alterations in DNA damage repair genes
    Meeting Abstract

    Mota, J. M.; Barnett, E.; Nauseef, J.; Stopsack, K. H.; Wibmer, A. G.; Danila, D. C.; Rathkopf, D. E.; Slovin, S. F.; Kantoff, P. W.; Scher, H. I.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Pretreatment eosinophil counts (PEC) in metastatic urothelial carcinoma (mUC) treated with anti-PD1/PD-L1 checkpoint inhibitors (CPI)
    Meeting Abstract

    Mota, J. M.; Teo, M. Y.; Whiting, K.; Ostrovnaya, I.; Li, H.; Lee, C. H.; Funt, S. A.; Callahan, M. K.; Iyer, G.; Bajorin, D. F.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Morris, M. J.; Heller, G.; Bryce, A. H.; Armstrong, A. J.; Beltran, H.; Hahn, O. M.; McGary, E. C.; Mehan, P. T.; Goldkorn, A.; Roth, B. J.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A phase Ill, multicenter study to assess the diagnostic performance and clinical impact of (18)F-DCFPyL PET/CT in men with suspected recurrence of prostate cancer (CONDOR)
    Meeting Abstract

    Morris, M. J.; Pouliot, F.; Saperstein, L.; Rowe, S. P.; Gorin, M. A.; Josephson, D. Y.; Wong, J. Y. C.; Carroll, P.; Lin, T.; Stambler, N.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Influence of WNT and DNA damage response pathway alterations on outcomes in patients with unresectable metastatic colorectal cancer
    Meeting Abstract

    Mondaca, S.; Walch, H. S.; Nandakumar, S.; Chatila, W. K.; Hechtman, J. F.; Cercek, A.; Diaz, L. A.; Sanchez-Vega, F.; Kemeny, N. E.; Segal, N. H.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Baseline genomic and circulating tumor cell (CTC) correlative data from very high-risk (VHR), localized, node-negative prostate cancer patients
    Meeting Abstract

    McBride, S. M.; Zelefsky, M. J.; Spratt, D. E.; Paller, C. J.; Kollmeier, M.; Slovin, S. F.; Aghalar, J.; Hearn, J. W. D.; Den, R. B.; Deville, C.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features
    Meeting Abstract

    McDermott, D. F.; Choueiri, T. K.; Motzer, R. J.; Aren, O. R.; George, S.; Powles, T.; Donskov, F.; Harrison, M. R.; Cid, J. R. R. R.; Ishii, Y.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Durability of complete response (CR) with atezolizumab (atezo) in locally advanced/metastatic urothelial carcinoma (mUC)
    Meeting Abstract

    Loriot, Y.; Balar, A. V.; Dreicer, R.; Hoffman-Censits, J. H.; Perez-Gracia, J. L.; Petrylak, D. P.; Van der Heijden, M. S.; Shen, X.; Zhu, Q.; Ding, B.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial
    Meeting Abstract

    Li, B. T.; Shen, R.; Offin, M.; Buonocore, D. J.; Myers, M. L.; Venkatesh, A.; Razavi, P.; Ginsberg, M. S.; Ulaner, G. A.; Solit, D. B.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save